HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Reduced survivin expression and tumor cell survival during chronic hypoxia and further cytotoxic enhancement by the cyclooxygenase-2 inhibitor celecoxib.

Abstract
Hypoxia is a characteristic feature of advanced solid tumors and may worsen prognosis. The development of tumor-targeted and hypoxia-inducible gene therapy vectors holds promise to selectively deliver and express suicidal or cytotoxic genes in hypoxic regions of tumors. In this regard, the promoter of the survivin gene, which encodes an anti-apoptotic protein that is strongly expressed in tumor tissue, has received attention because of its supposed inducibility by hypoxia. However, in our present study we demonstrate that treatment of various tumor cell lines with chronic hypoxia or with the hypoxia-mimetic CoCl(2) does not result in increased expression of survivin, but rather strongly suppresses this gene's activity. In contrast, expression of glucose-regulated protein 78 (GRP78/Bip) is substantially elevated under chronic hypoxia in vitro and in hypoxic areas of tumor tissue in vivo. Although tumor cells in general exhibit increased chemoresistance under hypoxic conditions, we found that hypoxic glioblastoma cells are more sensitive to killing by the selective cyclooxygenase-2 (COX-2) inhibitor celecoxib, and this effect is reflected by further decreased expression of survivin. Intriguingly, 2,5-dimethyl-celecoxib (DMC), a close structural analog of celecoxib that lacks the ability to inhibit COX-2, is able to potently mimic the anti-tumor effects of its parent compound, indicating that inhibition of COX-2 is not involved in these processes. Taken together, our results caution against the use of survivin-based promoters to target hypoxic areas of tumors, but favor constructs that include the strongly hypoxia-inducible GRP78 promoter. In addition, our data introduce celecoxib as a drug with increased cytotoxicity against hypoxic tumor cells.
AuthorsAdel Kardosh, Nathaniel Soriano, Peter Pyrko, Yen-Ting Liu, Mark Jabbour, Florence M Hofman, Axel H Schönthal
JournalJournal of biomedical science (J Biomed Sci) Vol. 14 Issue 5 Pg. 647-62 (Sep 2007) ISSN: 1021-7770 [Print] England
PMID17440835 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • BIRC5 protein, human
  • Cyclooxygenase 2 Inhibitors
  • Endoplasmic Reticulum Chaperone BiP
  • HSPA5 protein, human
  • Inhibitor of Apoptosis Proteins
  • Microtubule-Associated Proteins
  • Neoplasm Proteins
  • Pyrazoles
  • Sulfonamides
  • Survivin
  • Cobalt
  • cobaltous chloride
  • Celecoxib
Topics
  • Celecoxib
  • Cell Hypoxia
  • Cell Line, Tumor
  • Cobalt (pharmacology)
  • Cyclooxygenase 2 Inhibitors (pharmacology)
  • Endoplasmic Reticulum Chaperone BiP
  • Humans
  • Inhibitor of Apoptosis Proteins
  • Microtubule-Associated Proteins (antagonists & inhibitors, genetics, metabolism)
  • Neoplasm Proteins (antagonists & inhibitors, genetics, metabolism)
  • Neoplasms (metabolism)
  • Pyrazoles (pharmacology)
  • Sulfonamides (pharmacology)
  • Survivin

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: